Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2025

Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: A target trial emulation study

Front. Immunol 2025;16:1673970 Doi: 10.3389/fimmu.2025.1673970

Bai WH,

Liao PL,

Bai YC,

Wei J CC

Bai et al. reported that JAKi therapy was associated with a reduced risk of incident uveitis compared with TNF inhibitors among patients with AS, PsO, or PsA. Authors conducted a large-scale, real world comparative study which evaluated the risk of incident uveitis among patients with psoriatic disease and AS treated with either TNFi or JAKi.

Keywords:

May 2025

Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis

J Am Acad Dermatol 2025;92:1015-23 DOI: 10.1016/j.jaad.2024.12.025

Chen TL,

Huang JY,

Lin HY,

Chang YT,

Li,

CY and Cheng-Chung Wei J

Chen et al. investigated the risk of MACE and VTE among patients with biologic-naïve psoriasis or PsA receiving biologic therapy. No significant difference in the risks of MACE and VTE was found between new biologics (IL-17i, IL-12/23i, or IL-23i) and TNFi.

Keywords:

April 2025

Interleukin‑23 versus Interleukin‑17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real‑World Comparison From the TriNetX US Collaborative Network

BioDrugs. 2025 Mar;39(2):297-306 doi: 10.1007/s40259-025-00705-5

Yu S,

Huo AP,

Wang YH,

Wei JC

IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups according to the latest real-world research from Yu S, et al.